| Epidemiology from Literature | | Cohort | Year | Country | Test | Subjects | Positive (%) | Bibliography | | 1.1 - Asymptomatic | 2014 | Belgium | IgE | 15 | 100.000 | 20140718, Faber MA
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | Belgium | IgE | 86 | 33.720 | 20101214, Gadisseur R
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | Italy | IgE | 16408 | 8.010 | 20100301, Scala E
| | 1.11 - Esophagitis, Diagnosed | 2013 | Netherlands | IgE | 76 | 42.100 | 20131020, van Rhijn BD
| | 1.11 - Esophagitis, Diagnosed | 2013 | Switzerland | IgE | 35 | 34.280 | 20130605, Simon D
| | 1.12 - Oral Allergy Syndrome | 2014 | Belgium | IgE | 38 | 100.000 | 20140718, Faber MA
| | 1.2.1 - Asthma, Diagnosed (Adults) | 2012 | Sweden | IgE | 96 | 47.920 | 20120528, Patelis A
| | 1.4 - Respiratory Symptoms, Diagnosed | 2012 | France | IgE | 129 | 8.500 | 20121204, Caimmi D
| | 1.4 - Respiratory Symptoms, Diagnosed | 2005 | Germany | IgE | 132 | 32.600 | 20050605, Mediaty A
| | 1.4 - Respiratory Symptoms, Diagnosed | 2014 | Italy | IgE | 21 | 23.800 | 20141114, Costa C
| | 1.4 - Respiratory Symptoms, Diagnosed | 2011 | Spain | IgE | 68 | 4.400 | 20110509, Rodriguez D
| | 1.5 - Atopic Dermatitis, Diagnosed | 2014 | Belgium | IgE | 14 | 0.000 | 20140718, Faber MA
| | 1.5 - Atopic Dermatitis, Diagnosed | 2013 | Germany | IgE | 140 | 31.430 | 20130111, Ott H
| | 1.5 - Atopic Dermatitis, Diagnosed | 2009 | Germany | IgE | 20 | 55.000 | 20091005, Ott H
| | 1.5 - Atopic Dermatitis, Diagnosed | 2005 | Germany | IgE | 113 | 23.900 | 20050605, Mediaty A
| | 1.5 - Atopic Dermatitis, Diagnosed | 2014 | Korea, Republic of | IgE | 25 | 4.000 | 20140821, Choi JS
| | 1.5 - Atopic Dermatitis, Diagnosed | 2014 | Netherlands | IgE | 211 | 64.500 | 20140331, Rockmann H
| | 1.6 - Anaphylaxis, Diagnosed | 2014 | Belgium | IgE | 37 | 32.430 | 20140718, Faber MA
| | 1.8 - Fruit Allergy | 2012 | Spain | IgE | 212 | 20.000 | 20120912, Palacin A
| | 1.9 - Pollen Allergy | 2014 | Czech Republic | IgE | 826 | 54.200 | 20140606, Panzner P
| | 1.9 - Pollen Allergy | 2012 | Spain | IgE | 117 | 14.000 | 20120912, Palacin A
| | 10.1 - Normal Control | 2014 | Belgium | IgE | 15 | 0.000 | 20140718, Faber MA
| | 10.1 - Normal Control | 2012 | Belgium | IgE | 27 | 0.000 | 20110223, De Knop KJ
| | 10.1 - Normal Control | 2009 | Belgium | IgE | 26 | 0.000 | 20091121, Ebo DG
| | 3.1.1 - Source Sensitized (SPT) | 2003 | Italy | IgE | 402 | 39.300 | 20031005, Mari A
| | 3.1.1 - Source Sensitized (SPT) | 2001 | Italy | IgE | 145 | 57.100 | 2001, Mari A
| | 3.2.1 - Source Sensitized (IgE) | 2003 | Austria | IgE | 10 | 95.000 | 2003a, Westritschnig K
| | 3.2.1 - Source Sensitized (IgE) | 2005 | Finland | IgE | 55 | 85.000 | 20041224, Moverare R
| | 3.2.1 - Source Sensitized (IgE) | 2008 | Japan | IgE | 55 | 43.600 | 20080319, Morita A
| | 3.2.1 - Source Sensitized (IgE) | 1999 | Netherlands | IgE | 223 | 63.200 | 1999, Van Ree R
| | 3.2.1 - Source Sensitized (IgE) | 2005 | Russian Federation | IgE | 5 | 60.000 | 20041224, Moverare R
| | 3.2.1 - Source Sensitized (IgE) | 2010 | Sweden | IgE | 100 | 90.000 | 20100212, Asarnoj A
| | 3.2.1 - Source Sensitized (IgE) | 2003 | Zimbabwe | IgE | 3 | 0.000 | 2003a, Westritschnig K
| | 4.1.1 - Heterologous Source Sensitized (Symptoms) | 2013 | Netherlands | IgE | 82 | 92.680 | 20130415, Masthoff LJ
| | 4.1.1 - Heterologous Source Sensitized (Symptoms) | 2013 | Netherlands | IgE | 79 | 81.010 | 20130415, Masthoff LJ
| | 4.1.1 - Heterologous Source Sensitized (Symptoms) | 2005 | Switzerland | IgE | 40 | 97.500 | 20050714, Ballmer-Weber BK
| | 4.1.1 - Heterologous Source Sensitized (Symptoms) | 2004 | Switzerland | IgE | 22 | 100.000 | 20040111, Mittag D
| | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 2003 | Spain | IgE | 76 | 6.600 | 20031017, Fernandez-Rivas M
| | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 2000 | Switzerland | IgE | 22 | 90.100 | 2000, Luttkopf D
| | 4.1.3 - Heterologous Source Sensitized (SPT) | 2013 | Italy | IgE | 18 | 61.110 | 20131031, Bonura A
| | 4.1.3 - Heterologous Source Sensitized (SPT) | 1999 | France | SPT | 11 | 0.000 | 1999a, Hoffmann-Sommergruber K
| | 4.1.3 - Heterologous Source Sensitized (SPT) | 1999 | Switzerland | SPT | 24 | 100.000 | 1999a, Hoffmann-Sommergruber K
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Austria | IgE | 54 | 33.300 | 20120310, Twaroch TE
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2009 | Belgium | IgE | 22 | 27.270 | 20091121, Ebo DG
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2013 | China | IgE | 38 | 50.000 | 20130624, Ma S
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Denmark | IgE | 30 | 83.000 | 20120410, Ballmer-Weber BK
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Denmark | IgE | 20 | 85.000 | 20120410, Ballmer-Weber BK
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2002 | Denmark | IgE | 24 | 100.000 | 2002, Luttkopf D
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Italy | IgE | 26 | 26.900 | 20120310, Twaroch TE
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Japan | IgE | 93 | 70.970 | 20120130, Fukutomi Y
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Japan | IgE | 21 | 100.000 | 20120130, Fukutomi Y
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Netherlands | IgE | 42 | 80.950 | 20120905, Le TM
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Spain | IgE | 20 | 0.000 | 20120410, Ballmer-Weber BK
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Spain | IgE | 9 | 22.000 | 20120410, Ballmer-Weber BK
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2010 | Spain | IgE | 50 | 6.500 | 20101124, Vereda A
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2011 | Sweden | IgE | 74 | 79.730 | 20110701, Moverare R
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2010 | Sweden | IgE | 35 | 82.900 | 20101124, Vereda A
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Switzerland | IgE | 21 | 95.000 | 20120410, Ballmer-Weber BK
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Switzerland | IgE | 20 | 100.000 | 20120410, Ballmer-Weber BK
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2002 | Switzerland | IgE | 19 | 100.000 | 2002, Luttkopf D
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2001 | Switzerland | IgE | 20 | 100.000 | 2001, Ballmer-Weber BK
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2013 | Thailand | IgE | 19 | 15.800 | 20131011, Suratannon N
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2010 | United States | IgE | 30 | 46.200 | 20101124, Vereda A
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2009 | Belgium | BPT | 20 | 65.000 | 20091121, Ebo DG
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2013 | China | IgE | 49 | 24.500 | 20130624, Ma S
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2013 | Italy | IgE | 96 | 35.410 | 20131128, Calamelli E
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2011 | Italy | IgE | 1084 | 73.610 | 20110211, DAvino R
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2013 | Slovenia | IgE | 37 | 35.140 | 20131106, Homsak M
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2010 | Sweden | IgE | 50 | 0.000 | 20100212, Asarnoj A
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2013 | Thailand | IgE | 21 | 0.000 | 20131011, Suratannon N
| | 4.1.6 - Heterologous Source Sensitized (High IgE) | 2011 | Austria | IgE | 60 | 98.330 | 20110211, DAvino R
| | 4.1.6 - Heterologous Source Sensitized (High IgE) | 2011 | Italy | IgE | 214 | 100.000 | 20110211, DAvino R
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2013 | Austria | IgE | 20 | 100.000 | 20130401, Berneder M
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2013 | Belgium | IgE | 21 | 80.950 | 20130401, Ebo DG
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Denmark | IgE | 21 | 85.710 | 20090406, Skamstrup Hansen K
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2007 | Denmark / Italy / Switzerland | IgE | 30 | 70.000 | 20070323, Ballmer-Weber BK
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2011 | Italy | IgE | 148 | 59.460 | 20110810, Pastorello EA
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2011 | Netherlands | IgE | 20 | 85.000 | 20110304, Vissers YM
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2012 | Spain | IgE | 233 | 0.000 | 20120726, Flores E
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2011 | Spain | IgE | 85 | 4.200 | 20110304, Garcia BE
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Spain | IgE | 20 | 15.000 | 20090406, Skamstrup Hansen K
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Switzerland | IgE | 24 | 92.000 | 20091005, Bauermeister K
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Switzerland | IgE | 21 | 95.230 | 20090406, Skamstrup Hansen K
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2000 | Switzerland | IgE | 22 | 90.900 | 2000, Luttkopf D
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2005 | Germany | HRT | 32 | 100.000 | 20050218, Erdmann SM
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | France | IgE | 51 | 92.100 | 1996, Pauli G
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2005 | Germany | IgE | 32 | 100.000 | 20050218, Erdmann SM
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Austria | IgE | 217 | 88.000 | 20141002, Deifl S
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Austria | IgE | 35 | 100.000 | 20141020, Guhsl EE
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Belgium | IgE | 99 | 79.800 | 20110223, De Knop KJ
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2013 | China | IgE | 16 | 87.500 | 20130510, Ma S
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2010 | Czech Republic | IgE | 178 | 89.900 | 20101026, Sekerkova A
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2011 | Germany | IgE | 258 | 92.630 | 20110327, Canis M
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2003 | Italy | IgE | 372 | 57.800 | 20030814, Rossi RE
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2004 | Netherlands / Switzerland | IgE | 20 | 100.000 | 20041204, Mittag D
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Sweden | IgE | 37 | 68.000 | 20140127, Konradsen JR
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Sweden | IgE | 28 | 79.000 | 20140127, Konradsen JR
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2009 | Switzerland | IgE | 20 | 90.000 | 20091005, Bauermeister K
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2005 | Switzerland | IgE | 21 | 100.000 | 20050714, Ballmer-Weber BK
| | 5.3.2 - Source Exposed (Symptoms, high IgE) | 2001 | Germany | IgE | 8 | 100.000 | 2001, Foetisch K
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2011 | Austria | IgE | 225 | 91.110 | 20110121, Geroldinger-Simic M
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2002 | Austria | IgE | 50 | 98.000 | 2002a, Moverare R
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2009 | Belgium | IgE | 37 | 100.000 | 20090826, Ebo DG
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2002 | Finland | IgE | 41 | 100.000 | 2002a, Moverare R
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2002 | France | IgE | 51 | 90.000 | 2002a, Moverare R
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2008 | Germany | IgE | 50 | 92.000 | 20081129, Treudler R
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2002 | Italy | IgE | 21 | 62.000 | 2002a, Moverare R
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 1996 | Italy | IgE | 65 | 69.200 | 1996, Rossi RE
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2004 | Poland | IgE | 14 | 64.000 | 20050112, Cudowska B
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2002 | Sweden | IgE | 42 | 98.000 | 2002a, Moverare R
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2002 | Switzerland | IgE | 37 | 65.000 | 2002a, Moverare R
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 1989 | Austria | IgE (IB) | 58 | 96.500 | 1989b, Jarolim E
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2000 | France | SPT | 29 | 100.000 | 2000, Pauli G
| | 5.4.2 - Source Exposed (Symptoms, SPT, high IgE) | 2003 | Switzerland | IgE | 34 | 97.100 | 20030814, Tresch S
| | 5.4.2 - Source Exposed (Symptoms, SPT, high IgE) | 1996 | Switzerland | IgE (IB) | 51 | 96.100 | 1996, Menz G
| | 5.4.2 - Source Exposed (Symptoms, SPT, high IgE) | 2003 | Switzerland | NPT | 23 | 91.300 | 20030814, Tresch S
| | 5.4.2 - Source Exposed (Symptoms, SPT, high IgE) | 2003 | Switzerland | SPT | 34 | 91.200 | 20030814, Tresch S
| | 5.4.2 - Source Exposed (Symptoms, SPT, high IgE) | 1996 | Switzerland | SPT | 51 | 100.000 | 1996, Menz G
| | 5.6.1 - Source Exposed (IgE) | 2009 | Austria | IgE | 9 | 100.000 | 20091216, Smole U
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2009 | Denmark | IgE | 20 | 100.000 | 20090406, Skamstrup Hansen K
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2009 | Spain | IgE | 17 | 17.650 | 20090406, Skamstrup Hansen K
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2009 | Switzerland | IgE | 20 | 100.000 | 20090406, Skamstrup Hansen K
| | 6.2 - General Population (Adults) | 2012 | Sweden | IgE | 371 | 13.480 | 20120528, Patelis A
| | 6.3 - General Population (Children) | 2003 | Sweden | IgE | 195 | 5.600 | 20030814, Kihlstrom A
| | 6.3 - General Population (Children) | 2003 | Sweden | IgE | 179 | 7.300 | 20030814, Kihlstrom A
| | 6.3 - General Population (Children) | 2002 | Sweden | IgE | 185 | 16.800 | 2002, Kihlstrom A
| | 6.3 - General Population (Children) | 2002 | Sweden | IgE | 180 | 10.000 | 2002, Kihlstrom A
| | 6.3 - General Population (Children) | 2002 | Sweden | IgE | 170 | 14.700 | 2002, Kihlstrom A
|
|
Loading...
Bet v 1
